Medpace Holdings, Inc. (MEDP): Cash & Equivalents
$497.05M
As of 2025-12-31
$502.69M
As of 2026-06-30
+160.0%
3-year compound annual growth
+12.3%
5-year compound annual growth
+42.0%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $497.05M | -25.8% | 2026-02-10, Balance as of period end |
| 2024-12-31 | $669.44M | +172.7% | 2026-02-10, Balance as of period end |
| 2023-12-31 | $245.45M | +768.4% | 2025-02-11, Balance as of period end |
| 2022-12-31 | $28.27M | -93.9% | 2024-02-13, Balance as of period end |
| 2021-12-31 | $461.30M | +66.1% | 2023-02-14, Balance as of period end |
| 2020-12-31 | $277.77M | +110.6% | 2022-02-15, Balance as of period end |
| 2019-12-31 | $131.92M | +466.8% | 2021-02-16, Balance as of period end |
| 2018-12-31 | $23.27M | -12.1% | 2020-02-25, Balance as of period end |
| 2017-12-31 | $26.48M | -28.6% | 2019-02-26, Balance as of period end |
| 2016-12-31 | $37.10M | +149.3% | 2018-02-27, Balance as of period end |
| 2015-12-31 | $14.88M | n/a | 2017-02-28, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | 2025-12-31 | $497.05M | -25.8% |
| Charles River Laboratories International, Inc. (CRL) | 2025-12-27 | $213.77M | +9.8% |
| Incyte Corp (INCY) | 2025-12-31 | $3.10B | +83.5% |
| Icon PLC (ICLR) | 2025-12-31 | $647.29M | +20.1% |
| Iqvia Holdings Inc. (IQV) | 2025-12-31 | $1.98B | +16.3% |
| NRC Health (NRC) | 2025-12-31 | $4.14M | -2.2% |
| MaxCyte, Inc. (MXCT) | 2025-12-31 | $20.07M | -28.0% |
| OmniAb, Inc. (OABI) | 2025-12-31 | $25.52M | -7.5% |
| Foxo Technologies Inc. (FOXO) | 2025-12-31 | $207.5K | +203.9% |
Compare MEDP, CRL, INCY, ICLR side by side · Screen every company in Services-Commercial Physical & Biological Research ↗